Nonalcoholic Fatty Liver Disease: A Clinical Review

Article

Nonalcoholic fatty liver disease may be the most common liver disease in the United States, with a high prevalence in the obese, type 2 diabetic population, and it is probably underestimated as a cause for cirrhosis. Clinicopathologically, it represents a wide spectrum of histologic abnormalities and clinical outcomes, ranging from benign hepatic steatosis to cirrhosis. Pathophysiologically, insulin resistance is thought to be pivotal in the development of steatosis, after which a second oxidative stressor produces lipid peroxidation and nonalcoholic steatohepatitis (NASH). Liver biopsy is the gold standard for diagnosis and prognosis. The need for an effective treatment is both clear and urgent, yet in the absence of proven therapies, treatment is directed toward weight loss and comorbidity management. For patients with NAFLD at risk of disease progression, there is a lack of large, randomized, placebo-controlled trials of adequate treatment duration, with baseline stratification according to histologic severity.

KEY WORDS:

nonalcoholic fatty liver disease nonalcoholic steatohepatitis insulin resistance obesity hyperlipidemia 

References

  1. 1.
    Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 346(16):1221–1231, 2002CrossRefPubMedGoogle Scholar
  2. 2.
    Ludwig J, Viggiano TR, McGill DB, Oh BJ: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55(7):434–438, 1980PubMedGoogle Scholar
  3. 3.
    Sheth SG, Gordon FD, Chopra S: Nonalcoholic steatohepatitis. Ann Intern Med 126(2):137–145, 1997PubMedGoogle Scholar
  4. 4.
    Schaffner F, Thaler H: Nonalcoholic fatty liver disease. Prog Liver Dis 8:283–298, 1986PubMedGoogle Scholar
  5. 5.
    Teli MR, James OF, Burt AD, Bennett MK, Day CP: The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 22(6):1714–1719, 1995PubMedGoogle Scholar
  6. 6.
    Angulo P, Lindor KD: Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 17(Suppl):S186–S190, 2002PubMedCrossRefGoogle Scholar
  7. 7.
    Tominaga K, Kurata JH, Chen YK, et al. : Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci 40(9):2002–2009, 1995PubMedCrossRefGoogle Scholar
  8. 8.
    Franzese A, Vajro P, Argenziano A, et al. : Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 42(7): 1428–1432, 1997CrossRefPubMedGoogle Scholar
  9. 9.
    Feldstein AE, El-Youssef M, Freese DK, Lindor KD, Angulo P: Nonalcoholic fatty liver disease in children: a follow-up study for up to 16 years. Gastroenterology 124(4; Supplement 1):A-701, 2003 (abstr)Google Scholar
  10. 10.
    Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M: Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 94(10):3010–3014, 1999PubMedCrossRefGoogle Scholar
  11. 11.
    Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M: Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 27(2):142–149, 1988PubMedGoogle Scholar
  12. 12.
    Luyckx FH, Desaive C, Thiry A, et al. : Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 22(3):222–226, 1998PubMedCrossRefGoogle Scholar
  13. 13.
    Wanless IR, Lentz JS: Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12(5):1106–1110, 1990PubMedCrossRefGoogle Scholar
  14. 14.
    Silverman JF, O’Brien KF, Long S, et al. : Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 85(10):1349–1355, 1990PubMedGoogle Scholar
  15. 15.
    Russo MW, Jacobson IM: Nonalcoholic fatty liver disease. Hosp Phy 67:36–41, 2002Google Scholar
  16. 16.
    Adams LA, Feldstein A, Lindor KD, Angulo P: Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 39(4):909–914, 2004PubMedCrossRefGoogle Scholar
  17. 17.
    Day CP, James OF: Steatohepatitis: a tale of two “hits”?. Gastroenterology 114(4):842–845, 1998PubMedCrossRefGoogle Scholar
  18. 18.
    Reid AE: Nonalcoholic steatohepatitis. Gastroenterology 121(3):710–723, 2001PubMedCrossRefGoogle Scholar
  19. 19.
    Pessayre D, Berson A, Fromenty B, Mansouri A: Mitochondria in steatohepatitis. Semin Liver Dis 21(1):57–69, 2001PubMedCrossRefGoogle Scholar
  20. 20.
    Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM: Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 94(6):2557–2562, 1997PubMedCrossRefGoogle Scholar
  21. 21.
    Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB: The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95(5):2111–2119, 1995Google Scholar
  22. 22.
    Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR: CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 105(8):1067–1075, 2000PubMedCrossRefGoogle Scholar
  23. 23.
    Uygun A, Kadayifci A, Yesilova Z, et al. : Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 95(12):3584–3589, 2000PubMedCrossRefGoogle Scholar
  24. 24.
    Chitturi S, Farrell G, Frost L, et al. : Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?. Hepatology 36(2):403–409, 2002PubMedCrossRefGoogle Scholar
  25. 25.
    Younossi ZM, Gramlich T, Bacon BR, et al. : Hepatic iron and nonalcoholic fatty liver disease. Hepatology 30(4):847–850, 1999PubMedCrossRefGoogle Scholar
  26. 26.
    Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA: Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 107(4):1103–1109, 1994PubMedGoogle Scholar
  27. 27.
    Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW: The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11(1):74–80, 1990PubMedCrossRefGoogle Scholar
  28. 28.
    Diehl AM, Goodman Z, Ishak KG: Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 95(4):1056–1062, 1988Google Scholar
  29. 29.
    Clark JM, Brancati FL, Diehl AM: The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98(5):960–967, 2003PubMedCrossRefGoogle Scholar
  30. 30.
    Sanyal AJ: AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123(5):1705–1725, 2002PubMedCrossRefGoogle Scholar
  31. 31.
    Angulo P, Keach JC, Batts KP, Lindor KD: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30(6):1356–1362, 1999CrossRefPubMedGoogle Scholar
  32. 32.
    Sonsuz A, Basaranoglu M, Ozbay G: Relationship between aminotransferase levels and histopathological findings in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 95(5):1370–1371, 2000PubMedCrossRefGoogle Scholar
  33. 33.
    Lee RG: Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 20(6):594–598, 1989CrossRefPubMedGoogle Scholar
  34. 34.
    Tajiri K, Takenawa H, Yamaoka K, Yamane M, Marumo F, Sato C: Nonalcoholic steatohepatitis masquerading as autoimmune hepatitis. J Clin Gastroenterol 25(3):538–540, 1997PubMedCrossRefGoogle Scholar
  35. 35.
    George DK, Goldwurm S, MacDonald GA, et al. : Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 114(2):311–318, 1998PubMedCrossRefGoogle Scholar
  36. 36.
    Rubbia-Brandt L, Leandro G, Spahr L, et al. : Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. Histopathology 39(2):119–124, 2001PubMedCrossRefGoogle Scholar
  37. 37.
    Hezode C, Lonjon I, Roudot-Thoraval F, Pawlotsky JM, Zafrani ES, Dhumeaux D: Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study. Aliment Pharmacol Ther 17(8):1031–1037, 2003PubMedCrossRefGoogle Scholar
  38. 38.
    Sanson-Fisher R: The measurement of alcohol consumption and alcohol-related problems. Austral Drug Alcohol Rev 5:309–310, 1986CrossRefGoogle Scholar
  39. 39.
    Lewis KO, Paton A: ABC of alcohol: tools of detection. Br Med J (Clin Res Ed) 283(6305):1531–1532, 1981CrossRefGoogle Scholar
  40. 40.
    Salaspuro M: Use of enzymes for the diagnosis of alcohol-related organ damage. Enzyme 37(1–2):87–107, 1987PubMedGoogle Scholar
  41. 41.
    Nalpas B, Vassault A, Charpin S, Lacour B, Berthelot P: Serum mitochondrial aspartate aminotransferase as a marker of chronic alcoholism: diagnostic value and interpretation in a liver unit. Hepatology 6(4):608–614, 1986PubMedCrossRefGoogle Scholar
  42. 42.
    Storey EL, Anderson GJ, Mack U, Powell LW, Halliday JW: Desialylated transferrin as a serological marker of chronic excessive alcohol ingestion. Lancet 1(8545):1292–1294, 1987PubMedCrossRefGoogle Scholar
  43. 43.
    Fletcher LM, Kwoh-Gain I, Powell EE, Powell LW, Halliday JW: Markers of chronic alcohol ingestion in patients with nonalcoholic steatohepatitis: an aid to diagnosis. Hepatology 13(3):455–459, 1991PubMedGoogle Scholar
  44. 44.
    Yajima Y, Ohta K, Narui T, Abe R, Suzuki H, Ohtsuki M: Ultrasonographical diagnosis of fatty liver: significance of the liver-kidney contrast. Tohoku J Exp Med 139(1):43–50, 1983PubMedCrossRefGoogle Scholar
  45. 45.
    Bydder GM, Chapman RW, Harry D, Bassan L, Sherlock S, Kreel L: Computed tomography attenuation values in fatty liver. J Comput Tomogr 5(1):33–35, 1981PubMedCrossRefGoogle Scholar
  46. 46.
    Mendler MH, Bouillet P, Le Sidaner A, et al. : Dual-energy CT in the diagnosis and quantification of fatty liver: limited clinical value in comparison to ultrasound scan and single-energy CT, with special reference to iron overload. J Hepatol 28(5):785–794, 1998PubMedCrossRefGoogle Scholar
  47. 47.
    Gore R: Diffuse liver disease. In Textbook of Gastrointestinal Radiology. Gore RM, Levine MS, Laufer I (eds). Philadelphia: Saunders, 1994, pp 1968–2017Google Scholar
  48. 48.
    Longo R, Pollesello P, Ricci C, et al. : Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging 5(3):281–285, 1995PubMedCrossRefGoogle Scholar
  49. 49.
    Saadeh S, Younossi ZM, Remer EM, et al. : The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123(3):745–750, 2002PubMedCrossRefGoogle Scholar
  50. 50.
    Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94(9):2467–2474, 1999PubMedCrossRefGoogle Scholar
  51. 51.
    Kleiner DE, Brunt EM, Van Natta ML, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu Y, Torbenson MS, Yeh M, McCullough AJ, Sanyal AJ: Design and validation of a histologic scoring system for NAFLD and NASH. Hepatology 38(4; Suppl 1):233A, 2003 (abstr)CrossRefGoogle Scholar
  52. 52.
    Contos MJ, Cales W, Sterling RK, et al. : Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 7(4):363–373, 2001PubMedCrossRefGoogle Scholar
  53. 53.
    Drenick EJ, Fisler J, Johnson D: Hepatic steatosis after intestinal bypass—Prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology 82(3):535–548, 1982PubMedGoogle Scholar
  54. 54.
    Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS: NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36(6):1349–1354, 2002PubMedGoogle Scholar
  55. 55.
    Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G: Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33(6):1358–1364, 2001CrossRefPubMedGoogle Scholar
  56. 56.
    Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116(6):1413–1419, 1999PubMedCrossRefGoogle Scholar
  57. 57.
    Harrison SA, Torgerson S, Hayashi PH: The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 98:2042–2047, 2003PubMedCrossRefGoogle Scholar
  58. 58.
    Caldwell SH, Oelsner DH, lezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ: Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29(3):664–669, 1999PubMedCrossRefGoogle Scholar
  59. 59.
    Ong J, Younossi ZM, Reddy V, et al. : Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 7(9):797–801, 2001PubMedCrossRefGoogle Scholar
  60. 60.
    Palmer M, Schaffner F: Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 99(5):1408–1413, 1990PubMedGoogle Scholar
  61. 61.
    Ueno T, Sugawara H, Sujaku K, et al. : Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 27(1):103–107, 1997CrossRefPubMedGoogle Scholar
  62. 62.
    Balkestein EJ, van Aggel-Leijssen DP, van Baak MA, Struijker-Boudier HA, Van Bortel LM: The effect of weight loss with or without exercise training on large artery compliance in healthy obese men. J Hypertens 17(12, Pt 2):1831–1835, 1999CrossRefPubMedGoogle Scholar
  63. 63.
    Alba LM, Lindor K: Review article: Non-alcoholic fatty liver disease. Aliment Pharmacol Ther 17(8):977–986, 2003PubMedCrossRefGoogle Scholar
  64. 64.
    Weinsier RL, Wilson LJ, Lee J: Medically safe rate of weight loss for the treatment of obesity: a guideline based on risk of gallstone formation. Am J Med 98(2):115–117, 1995PubMedCrossRefGoogle Scholar
  65. 65.
    DeWind LT, Payne JH: Intestinal bypass surgery for morbid obesity. Long-term results. JAMA 236(20):2298–2301, 1976Google Scholar
  66. 66.
    Naslund I: Gastric bypass versus gastroplasty. A prospective study of differences in two surgical procedures for morbid obesity. Acta Chir Scand Suppl 536:1–60, 1987Google Scholar
  67. 67.
    Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL: A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 96(2):519–525, 2001PubMedCrossRefGoogle Scholar
  68. 68.
    Tolman KG, Chandramouli J: Hepatotoxicity of the thiazolidinediones. Clin Liver Dis 7(2):369–379, 2003PubMedCrossRefGoogle Scholar
  69. 69.
    Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR: Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38(4):1008–1017, 2003CrossRefPubMedGoogle Scholar
  70. 70.
    Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Yanovski JA, Kleiner DE, Hoofnagle JH: A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39:188–196, 2004CrossRefPubMedGoogle Scholar
  71. 71.
    Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N: Metformin in non-alcoholic steatohepatitis. Lancet 358(9285):893–894, 2001PubMedCrossRefGoogle Scholar
  72. 72.
    Laurin J, Lindor KD, Crippin JS, et al. : Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 23(6):1464–1467, 1996PubMedCrossRefGoogle Scholar
  73. 73.
    Basaranoglu M, Acbay O, Sonsuz A: A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 31(2):384, 1999PubMedCrossRefGoogle Scholar
  74. 74.
    Lindor KD, Kowdley KV, Heathcote EJ, et al. : Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39(3):770–778, 2004PubMedCrossRefGoogle Scholar
  75. 75.
    Lavine JE: Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 136(6):734–738, 2000CrossRefPubMedGoogle Scholar
  76. 76.
    Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S: Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am Gastroenterol 98(11):2485–2490, 2003CrossRefGoogle Scholar
  77. 77.
    Adams LA, Angulo P: Vitamins E and C for the treatment of NASH: duplication of results but lack of demonstration of efficacy. Am J Gastroenterol 98(11):2348–2350, 2003PubMedCrossRefGoogle Scholar
  78. 78.
    Sanyal AJ, Contos MJ, Sargeant C, et al. : A randomized controlled pilot study of pioglitazone and vitamin E versus vitamin E for nonalcoholic steatohepatitis. Hepatology 36(4; Part 2 of 2):A-382, 2002 (abstr)Google Scholar
  79. 79.
    Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD: Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 96(9):2711–2717, 2001PubMedCrossRefGoogle Scholar
  80. 80.
    Miglio F, Rovati LC, Santoro A, Setnikar I: Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study. Arzneimittelforschung 50(8):722–727, 2000Google Scholar
  81. 81.
    Charlton M, Kasparova P, Weston S, et al. : Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 7(7):608–614, 2001CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  1. 1.Division of Gastroenterology, Hepatology and NutritionUniversity of Pittsburgh School of MedicinePittsburghUSA
  2. 2.Department of MedicineUniversity of CaliforniaDavisUSA
  3. 3.Division of Gastroenterology, Hepatology and NutritionUPMC Center for Liver DiseasesPittsburghUSA

Personalised recommendations